Is Mesoblast Limited (NASDAQ:MESO) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Mesoblast Limited at current levels.
Ryoncil's commercial ramp is the proof point that turns a 20-year stem cell story into a real revenue engine.
Where MESO is headed
Mesoblast spent two decades as the company that always seemed one trial readout away from validation. That changed when Ryoncil cleared the FDA for pediatric steroid-refractory acute graft-versus-host disease, and the first commercial doses started shipping through transplant centers. The revenue line went from rounding error to something measurable, and the question now is whether the company can do the harder thing, which is turn an approved orphan therapy into a multi-indication platform.
Read the full Compass Direction on MESO
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $14.52).
See the full MESO analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Mesoblast Limited (NASDAQ:MESO) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Mesoblast Limited at current levels. Ryoncil's commercial ramp is the proof point that turns a 20-year stem cell story into a real revenue engine.
What is MESO's Compass Score?
Mesoblast Limited scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for MESO?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the MESO page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.